Trial Search Results

Dose Escalation Study of OMP-54F28 in Combination With Paclitaxel and Carboplatin in Patients With Recurrent Platinum-Sensitive Ovarian Cancer

The purpose of this study is to test the safety of OMP-54F28 when combined with the chemotherapy drugs paclitaxel and carboplatin that are standard of care for ovarian cancer. The study is designed to test the safety of OMP-54F28 at different dose levels and the effects, both good and bad, that it has on ovarian cancer when combined with paclitaxel and carboplatin. Since OMP-54F28 has not been tested with paclitaxel and carboplatin in humans before, it is not known if it will provide any benefit and if it will cause harmful side effects.

Stanford is currently not accepting patients for this trial.

Lead Sponsor:

OncoMed Pharmaceuticals, Inc.

Stanford Investigator(s):

Intervention(s):

  • Drug: OMP-54F28, Paclitaxel and Carboplatin

Phase:

Phase 1

Eligibility


Inclusion Criteria:

   - Signed Informed Consent Form

   - Age ≥18 years

   - Histologically documented ovarian, primary peritoneal or fallopian tube cancer

   - Recurrent platinum-sensitive disease, defined as disease progression ≥6 months after
   completing a minimum of 4 cycles of a platinum-containing regimen

   - Availability of FFPE tumor tissue, either archival or obtained at study entry through
   fresh biopsy

   o Tumor tissue from fine needle aspiration is not acceptable.

   - ECOG performance status of 0 or 1

   - All acute treatment-related toxicity from prior therapy must have resolved to Grade ≤
   1 prior to study entry

   - Adequate hematologic and end-organ function

   - Evaluable or measurable disease per RECIST v1.1

   - For women of childbearing potential, agreement to use two effective forms of
   contraception

Exclusion Criteria:

   - Non-epithelial ovarian carcinoma, including malignant mixed Mullerian tumors

   - Prior treatment with paclitaxel and carboplatin for recurrent platinum-sensitive
   ovarian cancer

   - Treatment with any anti-cancer therapy, including radiotherapy, chemotherapy, biologic
   therapy, or herbal therapy within 3 weeks or 5 half-lives (for systemic agents),
   whichever is shorter

   - Known hypersensitivity to any component of study treatments that resulted in drug
   discontinuation

   - Grade ≥ 2 sensory neuropathy

   - Uncontrolled seizure disorder or active neurologic disease

   - Untreated brain metastases

   - Leptomeningeal disease as a manifestation of cancer

   - Active infection requiring antibiotics

   - Bisphosphonate therapy for symptomatic hypercalcemia

   - Known history of clinically significant liver disease, including active viral
   hepatitis and cirrhosis

   - Significant intercurrent illness including, but not limited to, unstable angina
   pectoris, and cardiac arrhythmia, or psychiatric illness/social situation that would
   limit compliance with study requirements

   - Pregnancy, lactation, or breastfeeding

   - Known HIV infection

   - Evidence of bleeding diathesis or significant coagulopathy (in the absence of
   therapeutic anticoagulation)

   - Concurrent use of therapeutic warfarin

   - New York Heart Association Classification III or IV

   - Known clinically significant gastrointestinal disease including, but not limited to,
   inflammatory bowel disease

   - Major surgical procedure, open biopsy, or significant traumatic injury within 28 days
   prior to the first dose of study treatment or anticipation of need for major surgical
   procedure during the course of the study

   - Osteoporosis based on a T-score of <-2.5 at the left or right total hip, left or right
   femoral neck or lumbar spine (L1-L4) as determined by DEXA scan

   - Bone metastases and one of the following:

      - Prior history of a pathologic fracture

      - Lytic lesion requiring an impending orthopedic intervention

      - Lack of treatment with a bisphosphonate or denosumab

   - Treatment with a thiazolidinedione PPAR gamma inhibitor; e.g. Actos® (pioglitazone)
   and Avandia® (rosiglitzone)

   - Active treatment with an oral or IV glucocortocoid for ≥4 weeks at a daily dose
   equivalent to or greater than 7.5 mg of oral prednisone

   - Fasting β-CTX of >1000 pg/mL

   - Metabolic bone disease, such as hyperparathyroidism, Paget's disease or osteomalacia

Ages Eligible for Study

18 Years - 90 Years

Genders Eligible for Study

Female

Not currently accepting new patients for this trial

Contact Information

Stanford University
School of Medicine
300 Pasteur Drive
Stanford, CA 94305
CCTO
650-498-7061
Not Recruiting